ReviewAAPS PharmSciTech2025
Personalized Vaginal Drug Delivery through 3D Printing: Techniques, Challenges, and Future Perspectives.
Review in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaginal disorders in reproductive‑age women, including bacterial vaginosis (affecting 23-29%), endometriosis, etc., are increasing alarmingly day by day worldwide. Vaginal drug delivery (VDD) has garnered notable attention in the pharmaceutical field for the localized and systemic treatment of several hormonal and gynaecological conditions. Conventional treatments remain inadequate due to high relapse rates, local and systemic side effects, compliance, invasiveness, drug resistance, adherence, safety, etc. Additive manufacturing, particularly 3D Printing (3DP), is reshaping pharmaceutical sciences by enabling the fabrication of personalized and novel drug delivery solutions. In addition, 3D Printed VDD systems (VDDS) offer highly customized and patient-specific dosage forms that possess controlled release kinetics and precise control over drug deposition, ultimately leading to increased patient adherence. This review comprehensively examines the state-of-the-art in 3DP technologies and critical considerations such as material selection, impact on drug release mechanisms, mechanical properties, and biocompatibility of the formulations, current regulatory landscape, and future perspectives of 3DP in VDD. This eventually paves the way for better patient-centered therapeutic solutions.
Indexed as
Identifiers
41299007What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.